Open access
Jul 2026
FREM1 promotes anlotinib resistance in non-small cell lung cancer through regulation of extracellular matrix organization.
FREM1 is identified as a candidate mediator of anlotinib resistance in NSCLC via regulation of ECM remodeling through silencing FREM1 potently reversed the anlotinib-induced suppression of key ECM components.
Yi Dong, Jingjing Zhang, Yuyang Zhao et al.
· Discover Oncology · 0 citations